Biomerica, Inc.
BMRA
$2.38
-$0.02-0.63%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -26.04% | -23.63% | -32.89% | 10.03% | 4.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.04% | -23.63% | -32.89% | 10.03% | 4.40% |
| Cost of Revenue | -3.34% | -37.02% | -9.40% | -5.66% | -3.46% |
| Gross Profit | -88.33% | 46.71% | -1,320.00% | 112.75% | 34.46% |
| SG&A Expenses | 4.94% | -2.21% | -16.76% | -32.89% | -22.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.75% | -21.32% | -12.52% | -22.80% | -17.20% |
| Operating Income | -38.27% | 18.27% | -2.36% | 39.50% | 38.25% |
| Income Before Tax | -37.99% | 100.38% | -8.84% | 39.03% | 36.42% |
| Income Tax Expenses | 266.67% | -25.00% | -28.57% | -200.00% | -137.50% |
| Earnings from Continuing Operations | -38.95% | 100.15% | -8.66% | 39.36% | 36.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.95% | 100.15% | -8.66% | 39.36% | 36.96% |
| EBIT | -38.27% | 18.27% | -2.36% | 39.50% | 38.25% |
| EBITDA | -39.34% | 18.49% | -2.32% | 39.95% | 38.93% |
| EPS Basic | -2.25% | 100.13% | -3.61% | 46.84% | 38.06% |
| Normalized Basic EPS | -1.55% | 100.31% | -3.81% | 46.55% | 37.54% |
| EPS Diluted | -2.25% | 100.13% | -7.32% | 46.84% | 38.35% |
| Normalized Diluted EPS | -1.55% | 100.31% | -3.81% | 46.55% | 37.54% |
| Average Basic Shares Outstanding | 35.88% | 25.46% | 4.87% | 14.06% | 1.78% |
| Average Diluted Shares Outstanding | 35.88% | 25.46% | 4.87% | 14.06% | 1.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |